VolitionRx announces milestone in nucleosomes detection

VolitionRx (VNRX) announces a major technical milestone with the successful detection of nucleosomes in capillary blood from critically ill sepsis patients using its lateral flow prototype. This finger prick sample test could be used at the bedside, in the ER, or even at home in a self-test lateral flow kit, similar to COVID-19 or pregnancy testing, thereby greatly expanding the potential market beyond centralized lab testing. Volition has previously announced results demonstrating correlation between whole venous blood samples utilizing its lateral flow prototype, and those of Volition’s established automated Nu.Q nucleosome assay performed in a central laboratory. This study, part of the SUMMIT program, tested capillary blood samples from hospital patients in Intensive Care using a lateral flow finger-prick prototype and demonstrated the detection of nucleosomes in those samples. Results showed the feasibility of early detection of immune disruptions that can occur in a range of conditions including sepsis, simply and rapidly when using the test in a variety of settings, without the need to send a blood sample to a hospital laboratory for testing.